Mark Chilvers, MRCPCH, MD, BSc, MBChB
University of British Columbia, Vancouver, BC

The care of CF has been revolutionized by the development of small molecule therapies known as CFTR modulators. This has opened the field for precision medicine for CF patients based on the underlying CFTR variant. With the approval by Health Canada and recommendation by CADTH of newer CFTR modulators, the aim of this presentation is to give an overview of modulator therapy development, mechanism of action and impact on CF care. In addition, following the recent publication of the Canadian CFTR modulator guideline, the evaluation, monitoring and safety of modulator therapy will be reviewed. Finally, recent published data on newer modulator therapy will be presented.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • Understand the current CFTR modulators mechanism of action;
  • Provide an update on the clinical trials involving CFTR modulators; and
  • Review the impact of CFTR modulators in CF care.

CanMEDS Roles Addressed: Medical Expert, Scholar